-
The Today contraceptive sponge awaits the results of a Food and Drug Administration (FDA) review to return to the shelves in the United States. After being approved by the FDA in 1983, the sponge achieved considerable popularity before production was discontinued in 1995. Since then, Allendale (NJ) Pharmaceuticals has purchased rights to the Today sponge and has been working to bring the product back to the United States.
-
Strides are being made when it comes to herpes. New treatments are emerging, and an advanced clinical trial of a potential herpes vaccine now is under way.
-
The decision to move the levonorgestrel emergency contraceptive pill Plan B (Barr Laboratories, Pomona, NY) to over-the-counter status has been delayed by the Food and Drug Administration.
-
Direct distribution of birth control may be an effective strategy for school-based clinics wishing to remove barriers to contraceptive access, according to research findings from Minnesota public health officials.
-
Check the following web wites to get teen-friendly information to hare with your adolescent patients...
-
Clinicians now have a second option in treating trichomoniasis, which accounts for nearly one-third of the 15.4 million cases of sexually transmitted diseases (STDs) in the United States. The Food and Drug Administration (FDA) has approved Tindamax (tinidazole) for the treatment of trichomoniasis, giardiasis, intestinal amebiasis, and amebic liver abscess.
-
It may be time to update your practice. According to a new survey of Americans ages 18-35, about half of respondents did not realize that hepatitis A and hepatitis B can be sexually transmitted, and an equal number said they did not know the two are vaccine-preventable.
-
The condom breaks or the pill pack stays at home on a weekend vacation. What will happen next? In Canada, women in all provinces will be able to go directly to the drug store for behind-the-counter access to emergency contraception (EC), based on the direction of regulatory wheels now set in motion.
-
What is your approach when it comes to discussing intrauterine contraception? It may be time to update your practice, based on information presented at the recent clinical meeting of the Washington, DC-based American College of Obstetricians and Gynecologists (ACOG) and newly published research.
-
Add the latest research finding to your counseling on progestin-only injectable and implant contraception: Results from a large U.S. study provide further evidence that these types of birth control do not raise a womans risk of breast cancer.